Evidence map›Paper›PMID 42033190›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Polycystin-1 Controls Cell Cycle Kinetics, Cell Cycle Exit, and Differentiation of Neural Progenitor Cells.

Natalie Winokurow, Stefan Schumacher

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Natalie WinokurowInstitute of Molecular and Cellular Anatomy, Ulm University, Ulm, Germany.
Stefan SchumacherInstitute of Molecular and Cellular Anatomy, Ulm University, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In neocortical neurogenesis, neural progenitor cells (NPCs) give rise to diverse types of neurons. During this process, the balance between proliferation and differentiation, cell division mode determination, and cell fate specification are all intimately linked to the cell cycle of the NPCs. The cell cycle length hypothesis states that G1-phase lengthening switches NPCs from proliferative to neurogenic divisions. Meanwhile, however, the importance of S-phase shortening in differentiating NPCs emerges. Mutations in the polycystin-1 (PC1)- and polycystin-2 (PC2)-encoding genes are causative for the development of autosomal dominant polycystic kidney disease (ADPKD), a prominent feature of which is unbalanced cell proliferation. Here, we examine the impact of PC1 and PC2 on cell cycle kinetics, cell cycle exit, and the neuronal differentiation of NPCs. Loss-of-function analysis and cell-based assays demonstrate that NPCs with reduced PC1 expression exhibit a longer cell cycle with an increased S-phase duration. The cell cycle exit and the neuronal differentiation of these cells are significantly delayed. A strong tendency towards similar phenotypes is observed when reducing PC2 expression in NPCs. Thus, decreasing PC1 expression expands the pool of slowly cycling NPCs. These results highlight the significance of S-phase shortening in neurogenesis and may contribute to a better understanding of ADPKD pathophysiology.

Indexed as

Cell CycleCell DifferentiationNeural Stem CellsTRPP Cation ChannelsAnimalsCell ProliferationMiceNeurogenesisNeuronsTRPP Cation Channelsautosomal dominant polycystic kidney disease (ADPKD)cell cycleneurogenesispolycystin‐1polycystin‐2progenitor cells

Identifiers

PMID42033190
PMCPMC13109810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.